DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

June 4-8, 2021; Online at https://conferences.asco.org/am
Post-hoc analysis of the DREAMM-2 findings suggest that BCVA changes and patient-reported ocular symptoms are concordant with corneal exam findings after belantamab mafodotin treatment in the majority of cases.
Format: Microsoft PowerPoint (.ppt)
File Size: 457 KB
Released: June 5, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Gain key clinical insights with this slideset from Clinical Care Options (CCO) on how ADCs use for cancer therapy can cause ocular toxicity

Asim V. Farooq, MD Released: November 12, 2021

Review the data on ocular toxicity associated with the ADC, belantamab mafodotin, in this slideset from Clinical Care Options (CCO)

Paul G. Richardson, MD Released: November 12, 2021

Gain expert insights on managing ocular toxicity associated with ADCs in this slideset from Clinical Care Options (CCO)

Joann Kang, MD Released: November 12, 2021

Experts answer frequently asked questions on the management of relapsed or refractory multiple myeloma with BCMA-targeted agents, from a live Clinical Care Options (CCO) webinar

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Released: October 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.